Bio-Bridge Science entered into a cooperative agreement with the Institute of Basic Medical Sciences at the Chinese Academy of Medical Sciences to research and develop a human papillomavirus polyvalent vaccine using prokaryotic expression system.
This vaccine is designed to prevent infection by human papillomavirus types 6, 11, 16, 18, 31, 45, and 58. This is expected to provide broader protection than the current vaccine on the market and have much lower production costs, according to Bio-Bridge.
Under the agreement, Bio-Bridge has been granted the preferential right to develop the vaccine and enjoys a 60% interest in the project.
"We believe that our agreement with the Chinese Academy of Medical Sciences will enable us to solidify our research capability in China as we try to introduce more potential vaccine products in addition to our current vaccine pipeline,” explains Liang Qiao, chairman and CEO of Bio-Bridge.